GR1005807B - Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology - Google Patents

Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology

Info

Publication number
GR1005807B
GR1005807B GR20050100363A GR20050100363A GR1005807B GR 1005807 B GR1005807 B GR 1005807B GR 20050100363 A GR20050100363 A GR 20050100363A GR 20050100363 A GR20050100363 A GR 20050100363A GR 1005807 B GR1005807 B GR 1005807B
Authority
GR
Greece
Prior art keywords
liposomal
mlcrs
modulatory
controlled release
dendrimer
Prior art date
Application number
GR20050100363A
Other languages
Greek (el)
Other versions
GR20050100363A (en
Inventor
Αρισταρχος Παπαγιανναρος
Κωνσταντινος Δεμετζος
Original Assignee
Αρισταρχος Παπαγιανναρος
Κωνσταντινος Δεμετζος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Αρισταρχος Παπαγιανναρος, Κωνσταντινος Δεμετζος filed Critical Αρισταρχος Παπαγιανναρος
Priority to GR20050100363A priority Critical patent/GR1005807B/en
Publication of GR20050100363A publication Critical patent/GR20050100363A/en
Publication of GR1005807B publication Critical patent/GR1005807B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Liposomes composed either of natural or synthetic phospholipids or either lipids or lipoamines or lipids. A dendrimer - anticancer drug complex or dendrimer - bioactive product complex encapsulated or attached to the lipid bilayers of the liposomes lead to a new liposomal form called Modulatory Liposomal Controlled Release System (MLCRS). This new liposomal was characterized physicochemicaly and the release rate of the anticancer drug doxorubicin was studied and corellated to the increase of the therapeutic index of doxorubicin. The advantage of this limposomal system is the modulation of the controlles release of the anticancer drug that is fundamental for the improvement of the pharmacokinetic parameters and its pharmacological evaluation. The present invention is suitable for use for the treatment of cancer.
GR20050100363A 2005-07-13 2005-07-13 Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology GR1005807B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20050100363A GR1005807B (en) 2005-07-13 2005-07-13 Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20050100363A GR1005807B (en) 2005-07-13 2005-07-13 Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology

Publications (2)

Publication Number Publication Date
GR20050100363A GR20050100363A (en) 2007-02-15
GR1005807B true GR1005807B (en) 2008-02-06

Family

ID=38121813

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20050100363A GR1005807B (en) 2005-07-13 2005-07-13 Modulatory liposomal controlled release system (mlcrs): a new dosage form for encapsulating anticancer drugs based on liposomal and dendrimer technology

Country Status (1)

Country Link
GR (1) GR1005807B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6416785B1 (en) * 2000-08-23 2002-07-09 Biolitec Ag Molecular probes for targeting of cell density-indicating compounds
CA2523413A1 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds

Also Published As

Publication number Publication date
GR20050100363A (en) 2007-02-15

Similar Documents

Publication Publication Date Title
Petrilli et al. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection
Leanza et al. Pharmacological targeting of ion channels for cancer therapy: in vivo evidences
Preta New insights into targeting membrane lipids for cancer therapy
Eloy et al. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy
Kim et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice
Mota et al. Broad overview of engineering of functional nanosystems for skin delivery
Kroon et al. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo
MX2015012201A (en) Modified docetaxel liposome formulations.
Moghimipour et al. Transferrin targeted liposomal 5-fluorouracil induced apoptosis via mitochondria signaling pathway in cancer cells
GR20060100144A (en) Cancer treatment using oxaliplatin encapsulated into liposomes and co-encapsulation into the liposome particle of more than one pharmaceutical preparations, or genes
PT1156789E (en) THERAPY FOR HUMAN CANCERS USING CISPLATIN AND OTHER PHARMACIES OR GENES ENCAPSULATED IN LIPOSOMES
BRPI0608297A2 (en) liposome compositions
Tan et al. Targeting peptide-decorated biomimetic lipoproteins improve deep penetration and cancer cells accessibility in solid tumor
Hodgins et al. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy
Teymouri et al. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity
Alavi et al. Drug delivery of hydroxyurea to breast cancer using liposomes
Jang et al. 2-Hydroxyoleic acid-inserted liposomes as a multifunctional carrier of anticancer drugs
US20200030457A1 (en) Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
Guo et al. Recent progress in nanotechnology-based drug carriers for celastrol delivery
Handa et al. Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting
El-Senduny et al. Azadiradione-loaded liposomes with improved bioavailability and anticancer efficacy against triple negative breast cancer
Khazanov et al. Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application
Dhanasekaran et al. Emerging insights into mitochondria-specific targeting and drug delivering strategies: Recent milestones and therapeutic implications
Zhang et al. Preparation and evaluation of peptide-dendrimer-paclitaxel conjugates for treatment of heterogeneous stage 1 nonsmall cell lung cancer in 293T and L132 cell lines
EP1484332A2 (en) Lipid-based drug delivery system for administration of a drug substance

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20110202